Overview

Cabozantinib and Nivolumab for Carcinoid Tumors

Status:
Recruiting
Trial end date:
2022-12-26
Target enrollment:
Participant gender:
Summary
This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. - Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Bristol-Myers Squibb
Exelixis
Treatments:
Nivolumab